

Hikma Pharmaceuticals PLC

Results of 2025 Annual General Meeting

LONDON, 24 April 2025 Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (the ‘**Company**’ or ‘**Hikma**’) announces that its Annual General Meeting (‘**AGM**’) was held at Sofitel London St James, 6 Waterloo Place, London SW1Y 4AN earlier today (24 April 2025) and commenced at 11.30 am. All the proposed resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 16 (inclusive) were passed as ordinary resolutions and Resolutions 17 to 20 (inclusive) were passed as special resolutions. Resolutions 21 to 22 (inclusive) were passed as ordinary resolutions on which only Independent Shareholders (that is, excluding members of the Darhold Concert Party, in accordance with the City Code on Takeovers and Mergers) were entitled to vote.

Copies of the resolutions dealing with special business passed at the AGM have been submitted to the FCA’s Electronic Submission System and will be available from the National Storage Mechanism. Capitalised terms used but not otherwise defined in this announcement shall have the meanings given to them in the Notice of Meeting dated 19 March 2025.

The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the Notice of Meeting dated 19 March 2025) is set out below. The number of Ordinary Shares in issue at the close of business on 22 April 2025 was 234,719,686. At that time there were 12,833,233 Ordinary Shares held in treasury, which are not counted in the voting capital of the Company which, therefore, was 221,886,453.

Resolution	Votes For	% of Eligible Votes	Votes Against	% of Eligible Votes	Total Votes Cast	Total votes cast as a % of ISC ¹	Withheld ²
1. To receive the 2024 report and accounts	165,916,947	99.98%	25,032	0.02%	165,941,979	74.79%	1,306,504
2. To approve a final dividend of 48 cents per share	167,236,391	99.99%	101	0.01%	167,236,492	75.37%	11,991
3. To re-appoint PricewaterhouseCoopers LLP as Auditor	165,736,140	99.80%	324,240	0.20%	166,060,380	74.84%	1,188,103
4. To authorise the Audit Committee to determine the remuneration of the Auditor	166,976,846	99.84%	259,630	0.16%	167,236,476	75.37%	12,007
5. To re-elect Said Darwazah as a Director	159,872,112	96.63%	5,581,855	3.37%	165,453,967	74.57%	1,794,516
6. To re-elect Riad Mishlawi as a Director	165,620,901	99.04%	1,612,530	0.96%	167,233,431	75.37%	15,052
7. To re-elect Mazen Darwazah as a Director	158,508,255	95.06%	8,244,567	4.94%	166,752,822	75.15%	495,661
8. To re-elect Victoria Hull as a Director	164,823,607	98.84%	1,929,924	1.16%	166,753,531	75.15%	494,952
9. To re-elect Ali Al-Husry as a Director	165,206,365	98.86%	1,903,076	1.14%	167,109,441	75.31%	139,042
10. To re-elect Nina Henderson as a Director	166,343,333	99.47%	891,330	0.53%	167,234,663	75.37%	13,820
11. To re-elect Cynthia Flowers as a Director	166,327,864	99.46%	906,799	0.54%	167,234,663	75.37%	13,820

Resolution	Votes For	% of Eligible Votes	Votes Against	% of Eligible Votes	Total Votes Cast	Total votes cast as a % of ISC ¹	Withheld ²
12. To re-elect Douglas Hurt as a Director	166,338,974	99.47%	894,533	0.53%	167,233,507	75.37%	14,976
13. To re-elect Laura Balan as a Director	166,404,839	99.50%	829,824	0.50%	167,234,663	75.37%	13,820
14. To re-elect Dr Deneen Vojta as a Director	166,339,842	99.46%	894,796	0.54%	167,234,638	75.37%	13,845
15. To receive and approve the annual report on Remuneration	165,314,532	99.55%	745,734	0.45%	166,060,266	74.84%	1,188,217
16. To authorise the Directors to allot shares and grant rights to subscribe for shares	161,367,208	96.49%	5,868,306	3.51%	167,235,514	75.37%	12,969
17. To authorise the disapplication of pre-emption rights (General)	159,795,080	95.55%	7,438,019	4.45%	167,233,099	75.37%	15,384
18. To authorise the disapplication of pre-emption rights (Acquisition or Capital Investment)	150,608,461	90.06%	16,626,673	9.94%	167,235,134	75.37%	13,349
19. To authorise the Company to purchase Ordinary Shares	165,666,195	99.21%	1,314,296	0.79%	166,980,491	75.25%	267,992
20. To authorise the Company to hold general meetings on not less than 14 clear days' notice	161,269,635	96.43%	5,966,422	3.57%	167,236,057	75.37%	12,426
21. To approve the Rule 9 Waiver (Buyback Waiver) ³	103,445,950	93.41%	7,303,834	6.59%	110,749,784	49.91%	3,164,163
22. To approve the Rule 9 Waiver (2026 Awards Waiver) ³	105,601,900	95.35%	5,145,069	4.65%	110,746,969	49.91%	3,166,978

¹ Issued Ordinary Share capital of the Company (excluding treasury shares).

² A "withheld" vote is not a vote in law and is not counted in the calculation of the proportion of votes "for" or "against" a resolution.

³ In order to comply with the City Code on Takeovers and Mergers, only the votes cast by the independent shareholders were counted for the purposes of Resolutions 21 to 22.

Declaration of final dividend

The dividend of 48 cents per share will be paid on 1 May 2025 to shareholders on the register at the close of business on 21 March 2025. Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling. The exchange rate in respect of this dividend will be \$1.29 to £1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at circa \$1 to 0.708JD.

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC

Helen Middlemist

Group Company Secretary

+44 20 7399 2670